David Bautista/iStock Editorial via Getty Images
- Johnson & Johnson (NYSE:JNJ) said that a combination of their therapies, Rybrevant (amivantamab) and Lazcluze (lazertinib), yielded a better survival benefit in treating first-line non-small cell lung cancer with a certain mutation than AstraZeneca’s (NASDAQ:AZN) Tagrisso (osimertinib).
- The J&J combo